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Indolent non-Hodgkin’s lymphoma (iNHL) is a slow growing cancer affecting B-cells. These 
lymphomas are difficult to treat with radiation and chemotherapy, and patients eventually relapse 
and become resistant to therapy over time. Prognosis is worse for patients who do not respond to 
standard therapies, necessitating the development of novel drugs. Lead author Dr. Ajay Gopal of the 
Clinical Research Division and collaborators report promising results in The New England Journal of 
Medicine from a Phase 2 study with the targeted inhibitor idelalisib in treatment of iNHL patients 
relapsed or refractory to standard treatment. "Idelalisib and other similar agents shift the paradigm 
from toxic chemotherapy that can only be given for a limited period to time to safer chronic, oral, 
therapy that can potentially control the disease for long periods with fewer side effects," according to 
Dr. Gopal. 
Idelalisib is a small molecule inhibitor of phosphoinositide 3-kinase (PI3K) delta, an isoform of the 
lipid kinase found only in hematopoietic cells. This makes PI3Kdelta an attractive target for blood 
cancers, as its inhibition would in theory have limited toxicity against healthy cells in other tissues. 
PI3Kdelta is activated downstream of a number of receptors present on B cells, including the B-cell 
receptor, cytokine and chemokine receptors, and integrins. Notably, malignant B cells rely on 
PI3Kdelta activity for cell growth, survival, and motility (see figure).  
 Dr. Gopal contributed to all stages of the clinical trial including the design of the study, the treatment 
of patients, and the analysis and presentation of the data. The Phase 2 efficacy and safety study for 
idelalisib enrolled 125 iNHL patients aged 33 to 87 who did not respond to conventional therapies or 
had relapsed within six months of treatment. Patients were treated in the Seattle area and at 17 
additional institutions in the United States and Europe. The Seattle-based company Gilead 
Sciences, Inc. funded the clinical study. Patients received 150 milligrams of idelalisib twice daily. 
Tumors shrunk by at least half in 57 percent of patients that received idelalisib (95 percent 
confidence interval, 48 to 66), and in 6 percent of patients there was no detectable cancer. 
Responses were rapid and durable, with the median time to a response at 1.9 months and the 
median duration of response at 12.5 months. At the time of data cutoff, the median overall survival 
was 20.3 months (range, 0.7 to 22.0) and the median progression-free survival was 11 months 
(range, 0.03 to 16.6).  
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Idelalisib is a more targeted approach to treating cancer with fewer side effects than standard 
chemotherapies. The standard treatment for iNHL involves a combination of chemotherapy and 
rituximab, an antibody that targets the cell surface protein CD20 found on B cells. Life-threatening 
complications of these treatments include infections and bone marrow failure. The most common 
side effects of idelalisib treatment were diarrhea, fatigue, nausea, cough, and fever. Adverse cases 
of diarrhea and colitis occurred in 13 and 4 percent of patients respectively and were managed with 
adjustments in the drug dose. 
 Impressively, this clinical trial demonstrates that targeting a specific kinase can safely induce 
responses in the vast majority of treatment-refractory iNHL patients. Dr. Gopal says this approach 
"opens the door to kinase-targeted therapies that can yield low-toxicity control of these otherwise 
incurable diseases." Dr. Gopal compares this approach to the treatment of hypertension. "It is hard 
to cure hypertension, but as long as you control it you will not suffer the sequelae." 
 In the same issue of The New England Journal of Medicine, another clinical study demonstrated 
significant antitumor activity with idelalisib in combination with rituximab in chronic lymphocytic 
leukemia (CLL) patients who relapsed after previous treatments or were unable to undergo standard 
chemotherapy. Dr. John Pagel also of the Clinical Research Division was a contributor to the CLL 
study (Furman, et al. 2014). Thanks, in part, to positive results such as those reported in the two 
NEJM publications, idelalisib may be approved for treatment of iNHL and CLL in the near future. 
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The lipid kinase PI3Kdelta is activated downstream of a number of cell surface receptors present on 
B cells. In lymphomas, PI3Kdelta activity is increased to promote cancer cell growth, survival and 
motility. Idelalisib inhibits PI3Kdelta activity and selectively kills lymphoma cells. 
 
